At a glance
ClinicalIndex Comparison RecordN/ACompleted· 355 enrolled
Drug / intervention
Tyrosine kinase inhibitor (TKI) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Advanced Renal Cell Carcinoma Treatment Patterns and Unmet Needs Using Real World Claims and Electronic Medical Record Data.
In Brief
An observational study evaluating Tyrosine kinase inhibitor (TKI) and Immuno-oncology (IO) for Renal Cell Carcinoma (RCC). Completed, enrolled 355 participants across 1 site.
Detailed Summary
The study aims to assess treatment patterns and outcomes in advanced RCC patients in real world clinical practices across various real world databases. Four databases will be evaluated
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma (RCC)
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartDec 2019
First PostedMay 2020
Primary CompletionOct 2022
TodayJul 2026
First PostedMay 5, 2020
Enrollment StartDec 2, 2019
Primary CompletionOct 28, 2022
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 6.2 years ago
Interventions
Tyrosine kinase inhibitor (TKI)drug
TKIs
Immuno-oncology (IO)drug
IOs